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Abstract. Despite advances in management, bladder cancer 
remains a major cause of cancer related complications. 
Characterisation of gene expression patterns in bladder 
cancer allows the identification of pathways involved in its 
pathogenesis, and may stimulate the development of novel 
therapies targeting these pathways. Between 2004 and 2005, 
cystoscopic bladder biopsies were obtained from 19 patients 
and 11 controls. These were subjected to whole transcript-
based microarray analysis. Unsupervised hierarchical 
clustering was used to identify samples with similar expres-
sion profiles. Hypergeometric analysis was used to identify 
canonical pathways and curated networks having statistically 
significant enrichment of differentially expressed genes. 
Osteopontin (OPN) expression was validated by immuno-
histochemistry. Hierarchical clustering defined signatures, 
which differentiated between cancer and healthy tissue, 
muscle-invasive or non-muscle invasive cancer and healthy 
tissue, grade 1 and grade 3. Pathways associated with cell 
cycle and proliferation were markedly upregulated in 
muscle-invasive and grade 3 cancers. Genes associated with 
the classical complement pathway were downregulated in 
non-muscle invasive cancer. Osteopontin was markedly over-
expressed in invasive cancer compared to healthy tissue. The 
present study contributes to a growing body of work on gene 
expression signatures in bladder cancer. The data support an 
important role for osteopontin in bladder cancer, and identify 
several pathways worthy of further investigation.
Introduction
Carcinoma of the bladder is the most common urothelial 
malignancy, and is the 6th commonest cancer in the world by 
incidence (1). Despite significant improvements in manage-
ment, bladder cancer remains one of the commonest causes 
of cancer related mortality, ranked 6th and 11th in the UK in 
2008 in men and women, respectively (2). Additionally, cura-
tive surgery or radiotherapy commonly results in significant 
long-term morbidity.
Localised bladder cancer may be divided into either 
non-muscle invasive bladder cancer (NMIBC) or into muscle 
invasive bladder cancer (MIBC). While the former may 
be cured by transurethral resection, treatment of the latter 
requires radical local management using either cystectomy 
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or radical radiotherapy (with or without concurrent chemo-
therapy). Approximately a third of NMIBC tumours will 
recur and progress to muscle invasive over time (3). Several 
clinicopathological factors including tumour grade, stage, 
size, presence of carcinoma in situ, previous recurrence (4), 
and p53 status are associated with increased likelihood of 
progression. However, these factors are not currently clearly 
sufficient to identify patients who need more radical therapy 
at the outset. Similarly, stratification of patients with muscle 
invasive cancer into those most likely to recur or progress 
following local therapy would enable a more personalised 
approach to treatment.
Previous studies have employed microarrays to investigate 
gene expression profiles in bladder cancer (5-8). The identi-
fication of differentially regulated genes and gene networks 
allows the dissection of pathways and processes that are 
dysregulated in bladder cancer. This, in turn, provides invalu-
able clues relating to pathogenesis and moreover, may provide 
novel targets for drug development.
Here, we describe a study in which we profiled gene 
expression in 20 bladder cancer samples and compared this 
to 11 healthy urothelial samples. In addition to defining gene 
expression signatures for different subgroups, the study identi-
fied several genes and gene networks which are significantly 
deregulated in bladder cancer. These include osteopontin and 
the classical complement pathway. In this study we used the 
Affymetrix Human gene 1.0 ST array which is a whole tran-
script based array compared to many other studies which used 
arrays querying only the 3' end of transcripts.
Materials and methods
Patients and tumour samples. Cystoscopic tissue biopsies 
were collected between May 2004 and November 2005. Prior 
to undergoing cystoscopy, participants gave written informed 
consent for additional biopsies to be taken for this study during 
their medical procedure. Patients eligible for inclusion were 
those aged 18-80 years with a diagnosis of histologically 
confirmed superficial (NMIBC) or muscle invasive (MIBC) 
transitional cell carcinoma (n=14 and n=6, respectively), and 
who had not received any prior therapy. Control (C) samples 
were obtained from uninvolved tissues, for which no abnor-
malities were observed upon histological examination (n=11). 
Ten of these were paired with bladder cancer biopsies (4 non-
muscle invasive and 5 muscle invasive), while the last was from 
a patient without a diagnosis of malignancy. Demographic 
characteristics of the patient cohort are presented in Table I. 
MIBC samples displayed a basal immuno-phenotype.
Tumour samples for IHC analysis were obtained from 
the Liverpool Bioinnovation Hub Biobank (Liverpool, UK). 
Pathologically assessed samples used healthy bladder tissue 
(n=3) and MIBC tumour tissue (n=3).
Ethical considerations. Approval for the present study was 
obtained from the South Birmingham Local research ethics 
Committee. All participants gave written informed consent for 
their respective biopsies to be utilized in this study. Approval 
for further anaylsis was granted by the Liverpool Tissue Bank 
Ethics Committee (application no. 12-09). All participants 
Table I. Patient demographics.
Demographics Controls (n=11) NMIBC (n=14) MIBC (n=6)
Age in years
  median, range 79.2 (64-85.8) 70.8 (47.0-81.9) 80.14 (65.3-85.8)
Gender
  Male 8 (72.2) 11 (78.6) 3 (60.0)
  Female 3 (27.2) 3 (21.4) 2 (40.0)
Grade
  g1 N/A 6 (42.8) 0 (0)
  G2 N/A 1 (7.1) 0 (0)
  g3 N/A 7 (50.0) 6 (100)
T stage
  PT1 N/A 5 (35.7) 0 (0)
  PT1B N/A 1 (7.1) 0 (0)
  Pta N/A 8 (57.1) 0 (0)
  PT2 N/A 0 (0) 6 (100)
Recurrence
  No N/A 12 (92.3) 0 (0)
  Yes N/A 1 (7.7) 5 (100)
Survival in months (95% CI) N/A 81.2 (73.3-not estimatable) 12.26 (0-35.6)
N/A, not applicable.
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gave written informed consent for their respective biopsies to 
be used in biomedical analysis.
Tissue sample preparation. Tissue biopsy samples were snap- 
frozen and stored in liquid nitrogen prior to RNA extraction.
RNA isolation. Total RNA was extracted from each tissue using 
TrIzol (Invitrogen) prior to purification on silica (rNeasy 
Mini columns; Qiagen, Hilden, germany) according to the 
manufacturer's recommendation. An Agilent Bioanalyser was 
used to confirm rNA integrity and only samples having a rIN 
of 6.0 or more were used.
cDNA probe synthesis. A total of 200 ng of total RNA was 
converted to cDNA including targeted depletion of rRNA 
transcripts using a WT expression kit (Ambion, Cambridge, 
mA, USA) according to the manufacturer's procedures. 
Resultant cDNA was fragmented and biotin end labelled using 
an Affymetrix WT Terminal Labelling kit (Affymetrix, Santa 
Clara, CA, USA).
Microarray hybridisation analysis. Labelled cDNA was 
hybridised to Affymetrix Human gene 1.0 ST whole tran-
script-based arrays followed by washing and staining on an 
Affymetrix FS450 fluidics station. The Human gene 1.0 ST 
Array (Affymetrix) comprised 764,885 distinct 25-nt probes 
interrogating 28,869 annotated genes based on the March 
2006 (UCSC hg18, NCBI Build 36) human genome sequence 
assembly with comprehensive coverage of refSeq, ensembl 
and putative complete CDS genBank transcripts.
Signal collection and analysis. Arrays were scanned using 
an Affymetrix Scanner 3000 7g. Affymetrix Command 
Console was used for instrument control and data acquisition. 
All procedures were carried out according to the standard 
Affymetrix protocols. raw microarray data were submitted to 
Arrayexpress (Accession: e-MTAB-1560).
Statistical analysis of microarray data
Data transformation. robust multi-array averaging, adjusted 
for non-specific binding, (gCrMA) was used for normalisa-
tion and summarisation of the probe intensity signals (9,10). 
Data were subject to rMA background correction and quan-
tile normalisation across all chips (to ensure comparable mean 
and standard deviation of the probe intensities), prior to log2 
transformation and median polish probe set summarisation.
Array data quality estimation. The normalised unscaled stan-
dard error (NUSe) of each array was calculated to compare 
data variability between and within arrays (11). A NUSe value 
of 1.05 was set as the upper limit of acceptable quality.
Data analysis. Principal components analysis using a 
covariance dispersion matrix was performed to map high 
dimensional data of each sample to 3 dimensions for estima-
tion of clustering according to classification and identification 
of outlying samples.
A mixed model analysis of variance (ANOVA) including 
methods of moments estimation was used to identify differ-
ential expression between non-invasive tumours, invasive 
tumours and healthy bladder tissue. Batch effects were taken 
into consideration within the model. ANOVA was conducted 
including ‘patient’ as a factor, taking the paired samples 
into consideration. Differences in gene expression between 
tumours of differing grade, and also differential expres-
sion between tumour samples were assessed using the t-test. 
To correct for multiple testing, genes were considered to be 
significantly differentially expressed if a false discovery rate 
(FDr) adjusted P<0.05 was obtained. The false discovery 
rate was calculated as previously described (12). Those genes 
whose fold change expression level was found to significantly 
differ by ±2x or greater were used for further analysis.
Unsupervised hierarchical agglomerative clustering 
(euclidean distance with average linkage clustering) was used 
to identify samples with similar expression profiles.
MetaCore version 6.7 (genego, Inc., St. Joseph, MI, USA), 
IPA (Ingenuity Systems, redwood City, CA, USA) and DAVID 
Bioinformatics resource v 6.7 (13) were employed to identify 
canonical pathways and curated networks having statistically 
significant enrichment of differentially expressed genes. 
Pathways from MetaCore analysis filtered on FDr <0.05 
are presented in Results, unless otherwise stated. Univariate 
Cox proportional hazards regression analysis was performed 
to evaluate the association between disease progression and 
differential gene expression.
Meta-analysis. Meta-analysis was conducted using publicly 
available gene expression data from Gene Expression 
Omnibus (14). Out of the possible 12 datasets identified 
(gSe88, gSe89, gSe7476, gSe30522, gSe24152, gSe3167, 
gSe5287, gSe12630, gSe27448, gSe19915, gSe13507 and 
GSE5479), we selected two datasets using the same micro-
array platform (Affymetrix Human genome U133A array) 
with a large number of samples for further analysis. raw CeL 
files from gSe3167 (15) with 60 samples and gSe5287 (16) 
with 30 samples were imported into Partek genomic Suite 
(Partek, Inc., Chesterfield, MO, USA) and data were processed 
and differential genes identified following the same protocol 
described earlier for our own data. Clinico-pathological data 
for the datasets were kindly provided by the authors. The 
gSe3167 dataset contains superficial transitional cell carci-
noma (NMIBC) with surrounding carcinoma in situ (CIS) (13 
patients), without surrounding CIS lesions (15 patients), muscle 
invasive carcinoma (MIBC, 13 patients), CIS only (n=5) and 
healthy bladder (n=14). The gSe2587 dataset contains 30 
samples from patients with muscle invasive bladder cancer.
Immunostaining
Western blotting. Western blotting was performed to validate 
the specificity of anti-OPN antibody (AF1433; r&D Systems, 
Inc., Minneapolis, MN, USA) for subsequent IHC analysis. 
Protein lysates were prepared in rIPA buffer from a MIBC 
cell line, 253-J and a NMIBC cell line, rT112. Bradford was 
used for protein quantification. Proteins were separated by 
SDS-PAGE prior to transferring onto a PDVF membrane. 
Blocking was performed for 1 h with 10% milk, prior to 
overnight incubation in 1:1,000 dilution of AF1433. Secondary 
antibody was applied for 1 h before visualising using eCL. 
β-actin (ab8227; Abcam) was used to demonstrate equal 
protein loading.
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Immunohistochemistry. Conditions for IHC with AF1433 
were optimised in clear cell renal carcinoma and kidney FFPe 
sections, using a no primary antibody control, a goat Igg 
isotype control (AB-108-C; r&D Systems) and a negative tissue 
control-breast skin. Antigen retreval was performed using the 
PT-link at pH 9.0, prior to peroxidase block (Dako), 1-h primary 
antibody (1:50 AF1433) incubation at rT, 1-h secondary 
antibody incubation at rT (1:100) prior to visualisation with 
DAB Chromagen (Dako). Staining intensity was scored by a 
consultant pathologist. Briefly, staining intensity was graded as 
0 (negative), + (weak), ++ (moderate) and +++ (strong).
Results
Bladder cancer tissues exhibit specific gene signatures. A 
total of 418 genes were differentially expressed between 
Figure 1. Cell proliferation genes are upregulated in bladder cancer. (A) Principal components analysis. Segregation into groups by tissue type and tumour 
grade was assessed. (B) Hierarchical clustering segregates tumour samples from healthy tissue. Key shown on the right. The numbers at the bottom of each 
column correspond to patient serial numbers. Standardised intensity range -2 (green) to 2 (red), 0 (black) fold change. (C) genes involved in the initiation of 
mitosis are upregulated in bladder cancer (P=2.59x10-9). genes circled in red and blue were, respectively, upregulated or downregulated in cancer samples. The 
length of the bar is proportional to the degree of change in expression.
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cancer and control samples, using a fold change of at least 2.5, 
and a false discovery rate (FDr) of 0.05. Of these, 368 genes 
showed reduced expression in tumours, while 50 genes showed 
increased expression in tumours. Principal components 
analysis demonstrated segregation of samples by tissue type 
and tumour grade (Fig. 1A). Similarly, hierarchical clustering 
Figure 2. genes involved in myogenesis and eMT are dysregulated in bladder cancer. (A) genes involved in myogenesis were downregulated in cancer 
samples (P=1.22x10-10). The relative expression for each gene is depicted by the colour and intensity of the circle (blue, downregulation; red, upregulation). 
(B) Downregulation of genes involved in eMT in cancer samples  (P=1.41x10-9). Genes circled in blue exhibited reduced expression within the tumour samples 
relative to healthy bladder tissue. The length of the blue bar is proportional to the extent of downregulation.
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segregated healthy bladder tissue and bladder cancer into two 
groups (Fig. 1B).
multiple genes involved in proliferation were upregulated 
in bladder cancer samples as compared to healthy samples 
(P=2.59x10-9) (Fig. 1C). These included components of the 
cyclin-dependent kinase 1 (CDK1)/cyclin B complex, activa-
tion of which is required to drive progression from G2- to 
M-phase. Initiation of cyclin B transcription is carried out by 
FOXM1. Moreover, the equilibrium between nuclear import 
and export of cyclin B1 is influenced by its phosphorylation 
Figure 3. Classical complement genes are downregulated in NMIBC. (A) Hierarchical clustering showing clustering of NMIBC and healthy tissue samples, 
though complete separation is not established. A key is given on the right of the figure. The numbers at the bottom of each column correspond to patient 
serial numbers. Standardised intensity range -2 (green) to 2 (red), 0 (black) fold change. (B) genes associated with the classical complement pathway are 
downregulated in NMIBC (P=5.12x10-10).
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status by PLK1, which was also upregulated. The substrates of 
CDK1/cyclin B include Lamin B, leading to depolymerization 
of the lamin nuclear-cytoskeleton, and Kinesin-related motor 
protein eg5 (KNSL1), which associates with centrosomes and 
spindle apparatus.
Genes involved in myogenesis and epithelial-to-mesenchymal 
transition (EMT) are downregulated in cancer samples. Genes 
downregulated in cancer (compared to healthy tissue) included 
several which are involved in myogenesis (P=1.22x10 -10) 
(Fig. 2A). These included the myocyte enhancer factor, Mef2, 
which is expressed during myogenesis. Mef2 and MyoD 
interact leading to MyoD activation and hence the expression 
of myosin heavy and light chains. In addition, genes involved 
in EmT were also downregulated (P=1.41x10-9) (Fig. 2B). 
eMT is critical during myogenesis, particularly as the muscle 
precursor cells delaminate from the dermomyotome. Muscle 
precursors invade the developing tissue and differentiate into 
mature muscle cells.
Comparison of NMIBC and healthy bladder tissue. A specific 
comparison was also made between NMIBC and healthy 
tissue. This identified 410 genes, which were differentially 
expressed by ≥2.5-fold (P<0.05, false discovery rate). Of these, 
393 were downregulated in cancer, while increased expression 
was observed in 17 (data not shown). Hierarchical clustering 
generally segregated into two groups, but with additional 
branching in one cluster as shown in Fig. 3A.
Similar to the analysis comparing all bladder cancer 
samples to healthy samples, genes involved in smooth muscle 
Figure 4. Dysregulation of pathways in MIBC. (A) Hierarchical clustering of genes and samples showing segregation of muscle-invasive tumour samples 
and control samples into different clusters. A key is shown on the right of the figure. The numbers at the bottom of each column correspond to patient serial 
numbers. Standardised intensity range -1.9 (green) to 1.9 (red), 0 (black) fold change. (B) Pathway enrichment (MIBC vs. control samples).
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development and EmT were downregulated (P=4.8x10-12). 
Notably, genes associated with the classical complement 
pathway were strongly downregulated in NMIBC samples, 
which may indicate a mechanism for immune evasion 
(P=5.12x10-10) (Fig. 3B).
MIBC vs. healthy tissue. Hierarchical clustering showed 
segregation of MIBC and healthy samples into two groups 
(Fig. 4A). There were 404 genes that were altered by at 
least 3-fold (P<0.05 false discovery rate). Out of these, 107 
showed increased expression between invasive tumours and 
healthy samples, while 297 were decreased in expression. 
Pathways enriched for these differentially regulated genes are 
shown in Fig. 4B. genes involved in chromosome condensa-
tion in prometaphase were upregulated in invasive bladder 
cancer (P=2.75x10-15). Similarly, several regulators of the 
anaphase promoting complex (APC) were also upregulated 
(P=3.47x10-12). These included the kinases, PLK1 and CDK1.
Comparison of grade 1 and 3 NMIBC. A further comparison 
was made between gene expression profiles in grade 1 and 
3 bladder cancers, which identified 341 genes that were 
differentially regulated by at least 2-fold (FDr P<0.05). 
Hierarchical clustering clearly segregates between grade 1 
and 3 (Fig. 5A). enriched pathways are shown in Fig. 5B. 
Notably multiple pathways associated with cell cycle progres-
sion were upregulated in grade 3 tumours and multiple 
core cell cycle components were upregulated in grade 3 
tumours. genes involved in the metaphase checkpoint were 
particularly upregulated (P=3.06x10-17). A comparison was 
also made of genes that were upregulated both in grade 3 
compared to grade 1 NMIBC and in MIBC compared to 
healthy samples.
Comparing grade 3 NMIBC and MIBC. A total of 292 genes 
were differentially expressed 2 or more fold (P<0.05). Of 
these, 144 showed increased expression in MIBC while the 
remaining 148 exhibited decreased expression in MIBC. 
Hierarchical clustering resulted in clear segregation between 
the two groups. Table II lists genes that were differentially 
expressed by >5-fold in grade 3 NMIBC compared to MIBC. 
Among the genes most upregulated in MIBC were the 
proteinases. Overexpression and activation of proteinases, that 
destroy the connective tissue, are involved in various patho-
logical processes including tumour progression. The most 
proteolytic of enzymes are the metalloproteinases. The matrix 
metalloproteinases (MMPs) comprise a family of enzymes 
that collectively can degrade all components of the extracel-
lular matrix (eCM), these were upregulated in this study. For 
example, the matrix metalloproteinases MMP1 and MMP16 
were upregulated 4.8- and 2.6-fold, respectively in MIBC 
compared to NMIBC.
Further functional analysis using Database for Annotation, 
Visualization and Integrated Discovery (DAVID). A further 
analysis of 143 genes, which were upregulated in MIBC 
Table II. genes exhibiting >5 fold differential expression between grade 3 and MIBC (FDr P<0.05).
    Fold change
Gene ID RefSeq P-value (MIBC/NMIBC
Family with sequence similarity 83, member D FAM83D NM_030919 5.50e-06 7.87015
Retinoic acid receptor responder (tazarotene induced) 1 rArreS1 NM_206963 0.001291 5.96921
Centromere protein I CeNPI NM_006733 1.35e-05 5.92042
Fibronectin 1 FN1 NM_212482 0.000579 5.86325
Centromere protein F, 350/400 ka (mitosin) CeNPF NM_016343 0.000505 5.7622
N mannosidase, α, class 1C, member 1 MAN1C1 NM_020379 0.000401 5.52916
Topoisomerase (DNA) II α 170 kDa TOP2A NM_001067 0.00091 5.32363
TPX2, microtubule-associated, homolog (Xenopus laevis) TPX2 NM_012112 0.000892 5.27537
ras association (ralgDS/AF-6) domain family member 2 rASSF2 NM_014737 0.000644 5.04613
Anillin, actin binding protein ANLN NM_018685 0.000489 5.01334
Table III. DAVID functional annotation clusters.
Annotation cluster Enrichment score Count P-value
extracellular glycoproteins 6.47 37 2.7e-07
Serine-type endopeptidase inhibitor activity 3.29 7 7.90e-05
Negative regulation of immune system processes 2.21 6 4.60e-04
Zymogen (proteolytic enzyme precursors) 1.85 14 5.10e -04
Cell migration 1.33 9 1.40E-03
EGF 1.18 5 1.50E-02
Response to wounding 0.95 13 8.20E-04
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compared to NMIBC was performed using the DAVID data-
base. A summary of annotation clusters is given in Table III.
Meta-analysis of gene expression data. In order to validate our 
results, we used a meta-analysis of a larger dataset consisting 
of 90 samples, generated by the combination of two publicly 
available bladder cancer gene expression datasets (15,16). 
When we followed the same criteria used with our dataset 
for classifying MIBC and NMIBC, there were 29 NMIBC 
samples and 42 MIBC samples in the meta-analysis dataset. 
There were also 14 healthy bladder tissue samples, while 
the rest of the samples (carcinoma in situ) were not used in 
analysis.
A total of 4513 genes were differentially expressed in 
NMIBC compared to healthy tissue, when a cut-off of FDr 
<0.05 and fold-change >2.5 were applied. When compared 
with differential genes from our data, there were 118 genes 
common in both analyses. Surprisingly except for one gene, 
PELO, all the other genes showed concordant expression. This 
included all the 8 genes upregulated in NMIBC and 109 genes 
downregulated in NMIBC compared to healthy bladder tissue 
(data not shown).
When MIBC samples were compared with healthy bladder 
samples, with a filter of FDr <0.05 and fold-change >3, 3905 
genes were differentially expressed in the meta-analysis. 
A comparison with differential genes from our data under 
similar conditions and filtrations revealed 44 common genes. 
Similarly, the expressions of all except 2 genes (SerPINeB13 
and CASC5) were concordant in both the analyses. All the 
30 genes downregulated in MIBC compared to healthy tissue 
showed concordant expression, while 12 out of 14 genes highly 
expressed in MIBC in this study showed similar expression in 
the meta-analysis (data not shown).
Osteopontin protein is overexpressed in MIBC compared to 
healthy urothelium. In order to determine the validity of the 
Figure 5. Comparing grade 3 and 1 NMIBC. (A) Hierarchical clustering segregates grade 1 and 3 NMIBC samples. The numbers at the bottom of each column 
correspond to patient serial numbers. Standardised intensity range -2 (green) to 2 (red), 0 (black) fold change. (B) Pathway enrichment (grade 3 vs. grade 1 
NMIBC).
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microarray data, OPN expression was examined in MIBC 
(n=3) and healthy urothelial tissue (n=3) using the IHC 
technique. Statistical analysis using Welch's unpaired t-test 
revealed a significant difference (P=0.0286) between MIBC 
and healthy tissue, with MIBC displaying diffuse cytoplasmic 
OPN staining of moderate (++) intensity, whilst healthy 
urothelium was typically OPN negative (-) (Fig. 6).
Discussion
The present study contributes to a body of work that uses 
microarray data to profile bladder cancer, and provides fresh 
insights into pathways involved in its pathogenesis. Distinctive 
patterns of gene expression differentiating between NMIBC 
and MIBC, and between high and low grade cancers were 
identified.
A striking upregulation in pathways involved in cell cycle 
control was observed in comparisons of MIBC and NMIBC, 
and between grade 3 and grade 1 NMIBC tumours. A 
significant overlap was observed between genes upregulated 
in grade 3 NMIBC tumours and those upregulated in MIBC 
compared to healthy tissue and these genes were predomi-
nantly mapped to cell cycle control pathways. This is likely to 
reflect the increased aggressiveness and likelihood of progres-
sion of grade 3 NMIBC. This panel of genes may therefore be 
useful in predicting progression of NMIBC.
Cell cycle genes which were upregulated included anillin 
(>8-fold upregulation), a substrate of APC, which is involved 
in cytokinesis (17). Anillin is upregulated in various cancers 
including pancreatic (18) and renal carcinoma (19). TPX2, 
which is involved in spindle assembly (20), was also upregu-
lated.
This upregulation of cell cycle related genes in bladder 
cancer is not unexpected, and was similarly shown in a study 
by Zaravinos et al (21). Notably, several of the upregulated 
genes have been identified as potential therapeutic targets for 
bladder cancers. Inhibitors of TOP2A include anthracyclines 
and etoposide, two well-established chemotherapy agents. 
The anthracycline doxorubicin, for example, exhibits anti-
bladder cancer effects and is a component of the commonly 
employed MVAC regimen. PLK1 inhibitors are currently 
in phase 1 and 2 trials, and preliminary studies suggest 
that PLK1 inhibitors may reduce proliferation of bladder 
cancer cell lines (22). However, results obtained from a 
recent phase 2 study evaluating the efficacy of the PLK1 
inhbitor volasertib as a second-line treatment in patients with 
locally advanced or metastatic urothelial cancer, suggests 
that although volasertib was well-tolerated with an accept-
able safety profile the antitumour activity of volasertib was 
not suffecient for further evaluation as a monotherapy (23). 
Several CDK inhibitors are also currently in phase 1 and 2 
clinical trials.
The expression of osteopontin (OPN) ‘secreted phos-
phoprotein 1’, a matricellular protein, is strongly associated 
with malignancies (reviewed in ref. 24). Furthermore, OPN 
rNA-silencing in BC significantly attenuates tumour cell 
Figure 6. Comparing OPN protein expression in MIBC and healthy urothelial tissue. (A) Healthy urothelium displaying negative OPN immunostaining, with 
the presence of non-specific binding in urothelial tissue; (B) MIBC tissue exhibiting moderate (++) diffuse OPN immunostaining; (C) Isotype control, OPN 
expressing kidney tissue with polyclonal goat Igg antibody; (D) graphical representation of staining results, results are average of staining from 3 healthy 
urothelial samples, and 3 MIBCs, statistical analysis was performed using Welch's unpaired t-test (P=0.0286). All images are representative of the cohort. 
Scoring was performed by a pathologist. 
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invasion (25). The finding that OPN expression was strik-
ingly upregulated (>10-fold) in invasive bladder cancers 
compared with the healthy tissue is consistent with previous 
studies demonstrating upregulation of OPN in urothelial 
malignancy (22,26-28). Whilst OPN rNA expression data is 
well represented in BC tissue (28,29), protein expression data 
are limited (26,27). Therefore, OPN expression was exam-
ined between MIBC and healthy urothelium to determine 
whether commonality between rNA and protein expression 
exists in BC. OPN was found to be signifcantly (P=0.0286) 
overexpressed in MIBC compared to healthy urothelium. 
These data are consistent with obeservations in gastric (30), 
oesophageal (31), cervical (32) and prostate (33) cancers 
(26,34). Whilst a significant relationship between OPN and 
poor prognosis was noted in upper urinary tract urothelial 
cell carcinoma no correlation between stage and grades was 
found (27). Conversely, OPN expression is associated with 
improved survival in pancreatic adenocarcinoma (35).
Elevated levels of osteopontin have also been detected in 
the plasma of patients with advanced transitional cell carci-
noma (TCC), suggesting that OPN could be a novel biomarker 
of disease stage (36,37). The utility of OPN expression as a 
prognostic marker (and/or predictor of treatment response), 
however, remains unproven (26,27,38). The differences in OPN 
expression (in blood and tissue) observed in studies could be 
explained, at least in part, by the expression of OPN isoforms. 
Specifically, OPN splice variants which exhibit divergent 
biological functions are differentially expressed in cancers. 
Intriguingly, CD44, the hyaluronic acid receptor, for which 
osteopontin is a key ligand (37), was found to be upregulated 
among invasive bladder cancers, further supporting a potential 
role for OPN in pathogenesis of TCC.
When comparing grade 3 NMIBC with MIBC, we 
observed an overexpression of the cell-matrix interaction 
network. In particular, there was upregulation in proteolytic 
enzymes such as the matrix metalloproteases (MMPs). This is 
consistent with the increased ability of MIBC to invade local 
tissues. It would be important to evaluate if overexpression of 
MMPs predicts NMIBC progression.
genes involved in myogenesis and epithelial-to-mesen-
chymal transition (eMT) were downregulated in tumours, and 
this was particularly noted in NMIBC samples compared with 
the healthy tissue. This is intriguing, and could represent an 
inhibitory effect of bladder cancer on normal bladder muscle 
growth. eMT describes a process by which epithelial cells lose 
their characteristic apical-basal polarity, intercellular junc-
tions and epithelial markers, while upregulating mesenchymal 
markers, acquiring front-rear polarity, and undergoing cyto-
skeleton reorganization into mesenchymal cells (39). eMT 
is associated with invasive cancers and metastases, portends 
a poor prognosis in patients with bladder cancer (40). In the 
present study, tumour samples were not micro-dissected, and 
the possible ‘admixture’ with normal muscle tissue within 
samples could have confounded the analysis of myogenesis 
and EmT genes.
One novel finding in this study is the downregulation of 
genes involved in the classical complement pathway within the 
NMIBC group. Previously, others  have shown that comple-
ment inhibitors such as CD46 and complement factor H 
(CFH) are upregulated in bladder cancers (41). The aggregate 
data suggest that repression of complement activity is an 
important pathogenic mechanism in bladder cancer develop-
ment. Intriguingly, CFH binds to the OPN protein and masks 
putative enzymatic-cleavage sites, and could thereby, alter 
OPN activity. Urinary levels of CFH were also investigated 
as markers of bladder malignancy (42,43), but were found to 
exhibit low sensitivity and specificity. This could be explained 
by changes in CFH levels during disease progression, and 
supports our findings that downregulation of complement 
genes occurred in NMIBC rather than MIBC samples.
eSrP1 and eSrP2 are upregulated in NMIBC (compared 
to healthy tissue), and are involved in the regulation of FgFr2 
splicing (44). While decreased expression of FgFr2b (one of 
the FGFR2 splice variants) was observed in a subset of bladder 
cancers (45), upregulation of FGFR2c (another splice variant) 
was detected in a bladder cancer metastasis model (46). 
Consistent with reports on differential protein isoforms during 
cancer development, our findings support the hypothesis that 
differential expression of FGFR2 splice variants is an impor-
tant pathogenic mechanism in bladder cancer. In agreement 
with data published from the Cancer Genome Atlas Reseach 
Network in 2013 (47) which comprehensively evaluated the 
molecular signature of 131 urothelial carcinomas and revealed 
that mutational spectrum was involved in cell cycle regulation, 
chromatin regulation, and kinase signalling pathways with 
potential therapeutic application, the present study highlights 
several dysregulated transcripts in BC that potentially could 
be targeted in BC treatment.
Whilst the long-term clinical outcome data would have 
allowed more robust conclusions to be drawn from the small 
cohort, meta-analysis of the microarray data together with 
the protein expression experiment highlight the importance 
of the presented data, in addition to the role of OPN in inva-
sion (25). Furthermore, this study supplements a growing body 
of molecular data in bladder cancer allowing further under-
standing of this complex and heterogeneous disease.
In conclusion, this study complements the published litera-
ture, and gives credence to observed associations between 
patterns of gene signatures with the stage and grade of bladder 
cancers. Ultimately such signatures would be most clinically 
useful if they improve prognostication of disease, particu-
larly among NMIBC, where a more aggressive therapeutic 
approach could be employed in cancers that were more likely 
to progress. The present study identified expression patterns, 
which may help this prediction (such as proteolytic enzymes), 
and these may be incorporated into future prospective studies. 
Significantly, we also identified several genes and pathways 
(such as OPN and the classical complement pathway) which 
were strikingly deregulated in bladder cancer, and which may 
be valuable drug targets.
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